Use of Impedance Cardiography and Applanation Tonometry for Prediction of the Antihypertensive Effect. Comparison Between an ATII Receptor Antagonist and a Diuretic.
Overview
- Phase
- Not Applicable
- Intervention
- Olmesartan
- Conditions
- Arterial Stiffness
- Sponsor
- AHEPA University Hospital
- Enrollment
- 60
- Locations
- 1
- Primary Endpoint
- Pulse wave velocity
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
The principal aim of the study is to determine whether the hemodynamic parameters measured with the two methods -impedance cardiography and applanation tonometry- can be predictive of the antihypertensive effect of two different classes of drugs, ATII antagonists and diuretics.
The drugs that will be used in the study are olmesartan and chlorthalidone and the duration of the study is 12 months.
The other basic aim of the study is to determine whether there is a difference (>6mmHg) between the two drugs regarding the reduction of the mean 24hour blood pressure and the effect of them on the hemodynamic parameters.
The hemodynamic parameters that will be measured by applanation tonometry are augmentation index, central blood pressure and pulse wave velocity.
The hemodynamic parameters that will be measured by impedance cardiography are cardiac index, thoracic fluid content index, systemic vascular resistance index and others.
Detailed Description
The principal aim of the study is to determine whether the hemodynamic parameters measured with the two methods -impedance cardiography and applanation tonometry- can be predictive of the antihypertensive effect of two different classes of drugs, ATII antagonists and diuretics. The drugs that will be used in the study are olmesartan and chlorthalidone and the duration of the study is 12 months.
Investigators
Maria Pikilidou, MD, MSc, PhD
Post-doctoral researcher
AHEPA University Hospital
Eligibility Criteria
Inclusion Criteria
- •Age \> 18 years
- •Drug naive patients with 1st or 2nd grade Arterial Hypertension according to the ESH/ESC guidelines 2013
- •The patient has signed the concent form
Exclusion Criteria
- •Secondary Hypertension
- •3rd grade of Arterial Hypertension
- •Chronic renal failure
- •Diabetes Mellitus
- •Sleep apnea syndrome
- •Chronic or acute inflammatory diseases
- •Stroke, myocardial infarction, angina pectoris in the past 6 months
- •Heart failure
- •Liver disease
- •Neoplasms
Arms & Interventions
Olmesartan
ARB administration (OLMESARTAN) at a starting dose and titrating at 15 weeks according to reach blood pressure target
Intervention: Olmesartan
Chlorthalidone
Diuretic administration (chlorthalidone) at a starting dose and titrating at 15 weeks according to reach blood pressure target
Intervention: Chlorthalidone
Outcomes
Primary Outcomes
Pulse wave velocity
Time Frame: 12 weeks
Measured by Sphygmocor devive
Secondary Outcomes
- Ambulatory blood pressure(12 months)
- Systemic vascular resistance(12 months)